Telitacicept 160mg

DRUG6 trials

Sponsors

RemeGen Co., Ltd., Renmin Hospital of Wuhan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The Affiliated Hospital of Xuzhou Medical University, Peking University First Hospital

Conditions

Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)Difficult-to-treat Rheumatoid ArthritisIgA NephropathyIgA Nephropathy (IgAN)Proliferative Glomerulonephritis With Monoclonal Immunoglobulin DepositsRheumatoid ArthritisSystemic Lupus Erythematosus (SLE)

Phase 1

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Active, not recruitingNCT06656962

Renmin Hospital of Wuhan UniversityAntineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)

Start: 2024-10-10End: 2026-10-30Updated: 2024-10-24

Phase 2

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

TerminatedNCT04905212

RemeGen Co., Ltd.IgA Nephropathy

Start: 2021-11-04End: 2023-11-09Updated: 2023-12-06

Telitacicept for PGNMID: A Single-Arm Study

Active, not recruitingNCT07111338

Peking University First HospitalProliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

Start: 2025-07-12End: 2027-05-29Target: 10Updated: 2025-08-08

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

RecruitingNCT07796516

Peking University People's HospitalDifficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis

Start: 2026-09-01End: 2028-06-30Target: 420Updated: 2026-09-01

Phase 3

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active, not recruitingNCT07098897

The Affiliated Hospital of Xuzhou Medical UniversityIgA Nephropathy (IgAN)

Start: 2024-08-01End: 2025-09-30Updated: 2025-08-01

Phase 4

Immune Cell Subsets in SLE Patients Treated with Telitacicept

Active, not recruitingNCT06677801

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySystemic Lupus Erythematosus (SLE)

Start: 2024-10-11End: 2027-10-31Target: 50Updated: 2024-11-07

Related Papers

Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study

CNS Neuroscience & Therapeutics2022-07-1831 citations